Additionally, MCH induces an upregulation in the transcription of anti-apoptotic protein Bcl2. Considering the observed benefits of MCH in enhancing survival, alleviating malnutrition, and reducing dyskinesia, we plan to further explore its potential as an adjunct therapy in AC treatment. The gene discussed is BCL2; the disease is Dyskinesia.